301 related articles for article (PubMed ID: 22928736)
21. Recent advances in inhibitors of C-terminal SRC kinase.
P O'Malley D
Future Med Chem; 2020 Aug; 12(16):1447-1449. PubMed ID: 32638626
[No Abstract] [Full Text] [Related]
22. Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase.
Zhang H; Xu D; Huang H; Jiang H; Hu L; Liu L; Sun G; Gao J; Li Y; Xia C; Chen S; Zhou H; Kong X; Wang M; Luo C
ACS Chem Biol; 2024 Apr; 19(4):999-1010. PubMed ID: 38513196
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
[TBL] [Abstract][Full Text] [Related]
24. 4-Aryl-4H-chromene-3-carbonitrile derivatives: evaluation of Src kinase inhibitory and anticancer activities.
Fallah-Tafti A; Tiwari R; Shirazi AN; Akbarzadeh T; Mandal D; Shafiee A; Parang K; Foroumadi A
Med Chem; 2011 Sep; 7(5):466-72. PubMed ID: 21801146
[TBL] [Abstract][Full Text] [Related]
25. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Apr; 94():9-25. PubMed ID: 25662515
[TBL] [Abstract][Full Text] [Related]
26. Novel patented SRC kinase inhibitor.
Lu XL; Liu XY; Cao X; Jiao BH
Curr Med Chem; 2012; 19(12):1821-9. PubMed ID: 22414081
[TBL] [Abstract][Full Text] [Related]
27. Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
Register AC; Chakraborty S; Maly DJ
Methods Mol Biol; 2017; 1636():79-89. PubMed ID: 28730474
[TBL] [Abstract][Full Text] [Related]
28. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
[TBL] [Abstract][Full Text] [Related]
30. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
31. Structure-based virtual screening of Src kinase inhibitors.
Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
[TBL] [Abstract][Full Text] [Related]
32. NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways.
Honda A; Kuramoto K; Niwa T; Naito H
Blood Cancer J; 2018 Jun; 8(7):62. PubMed ID: 29941953
[No Abstract] [Full Text] [Related]
33. Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors.
Nasrolahi Shirazi A; Tiwari RK; Brown A; Mandal D; Sun G; Parang K
Bioorg Med Chem Lett; 2013 Jun; 23(11):3230-4. PubMed ID: 23602444
[TBL] [Abstract][Full Text] [Related]
34. Structural basis for the inhibitor recognition of human Lyn kinase domain.
Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase.
Yen-Pon E; Li B; Acebrón-Garcia-de-Eulate M; Tomkiewicz-Raulet C; Dawson J; Lietha D; Frame MC; Coumoul X; Garbay C; Etheve-Quelquejeu M; Chen H
ACS Chem Biol; 2018 Aug; 13(8):2067-2073. PubMed ID: 29897729
[TBL] [Abstract][Full Text] [Related]
36. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J
J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 4,6-substituted-(diaphenylamino)quinazolines as potent c-Src inhibitors.
Li JR; Li DD; Fang F; Du QR; Lin L; Sun J; Qian Y; Zhu HL
Org Biomol Chem; 2013 Dec; 11(48):8375-86. PubMed ID: 24178241
[TBL] [Abstract][Full Text] [Related]
38. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment.
Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838
[TBL] [Abstract][Full Text] [Related]
40. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
Lou L; Yu Z; Wang Y; Wang S; Zhao Y
Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
